Hereditary Renal Cancer Syndromes
Medical Sciences · 2024
DOI: 10.3390/medsci12010012 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Medical Sciences, 2024. Verfasst von Grigory A Yanus und 2 weiteren Autor:innen. Beteiligte Einrichtung: Department of Medical Genetics, Saint-Petersburg State Pediatric Medical University, 194100 Saint-Petersburg, Russia. Hauptthemen laut MEDLINE: Carcinoma, Renal Cell, Kidney Neoplasms, Neoplastic Syndromes, Hereditary. Die Arbeit wurde bisher 17-mal zitiert (Crossref) und nennt 174 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Russian Science Foundation.
Abstract (Originalsprache)
Familial kidney tumors represent a rare variety of hereditary cancer syndromes, although systematic gene sequencing studies revealed that as many as 5% of renal cell carcinomas (RCCs) are associated with germline pathogenic variants (PVs). Most instances of RCC predisposition are attributed to the loss-of-function mutations in tumor suppressor genes, which drive the malignant progression via somatic inactivation of the remaining allele. These syndromes almost always have extrarenal manifestations, for example, von Hippel–Lindau (VHL) disease, fumarate hydratase tumor predisposition syndrome (FHTPS), Birt–Hogg–Dubé (BHD) syndrome, tuberous sclerosis (TS), etc. In contrast to the above conditions, hereditary papillary renal cell carcinoma syndrome (HPRCC) is caused by activating mutations in the MET oncogene and affects only the kidneys. Recent years have been characterized by remarkable progress in the development of targeted therapies for hereditary RCCs. The HIF2aplha inhibitor belzutifan demonstrated high clinical efficacy towards VHL-associated RCCs. mTOR downregulation provides significant benefits to patients with tuberous sclerosis. MET inhibitors hold promise for the treatment of HPRCC. Systematic gene sequencing studies have the potential to identify novel RCC-predisposing genes, especially when applied to yet unstudied populations.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Medical Genetics, Saint-Petersburg State Pediatric Medical University, 194100 Saint-Petersburg, Russia.
- Department of Tumor Growth Biology, N.N. Petrov National Medical Research Center of Oncology, 197758 Saint-Petersburg, Russia.
- Laboratory of Molecular Biology, Kurchatov Complex for Medical Primatology, National Research Centre "Kurchatov Institute", 354376 Sochi, Russia.
ORCID-Profile: Ekaterina Sh Kuligina, Evgeny N Imyanitov
Förderung
- Russian Science Foundation
Zitieren
APA
Yanus, G. A., Kuligina, E. S., & Imyanitov, E. N. (2024). Hereditary Renal Cancer Syndromes. Medical Sciences. https://doi.org/10.3390/medsci12010012
Vancouver
Yanus GA, Kuligina ES, Imyanitov EN. Hereditary Renal Cancer Syndromes. Medical Sciences. 2024. doi:10.3390/medsci12010012
BibTeX
@article{Yanus2024,
author = {Yanus, Grigory A and Kuligina, Ekaterina Sh and Imyanitov, Evgeny N},
title = {Hereditary Renal Cancer Syndromes},
journal = {Medical Sciences},
year = {2024},
doi = {10.3390/medsci12010012}
}
EUVIMED